Evaluation of Serum Preptin Levels in Patients With Polycystic Ovary Syndrome

Sponsor
GÜLDEN ANATACA
Study ID
NCT07736079
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Insulin Resistance
  • Polycystic Ovary Syndrome (PCOS)

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 45 Years
Healthy Volunteers
Not accepted

Study Details

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age and is strongly associated with insulin resistance and metabolic dysfunction. Preptin is a pancreatic peptide co-secreted with insulin and has been implicated in glucose metabolism and insulin resistance. However, limited data exist regarding serum preptin levels in patients with PCOS. The aim of this study is to evaluate serum preptin levels in women diagnosed with PCOS and to investigate the relationship between preptin levels and insulin resistance parameters.

Key Dates

First listed
Jul 30, 2026
Start date
Jul 30, 2026
Status verified
Jul 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: PCOS Group
    Patients diagnosed with PCOS according to the Rotterdam criteria.
  • Arm: Control Group
    Women presenting with similar complaints but not meeting Rotterdam diagnostic criteria for PCOS.

Primary Outcome Measure

Serum Preptin Concentration [ Time Frame: Baseline ]

Central Contacts

Related Studies